Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.

Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...

LEO Pharma and non-profit organisation DEBRA Research have announced a collaboration aimed at accelerating the development of treatments for epidermolysis bullosa (EB). The non-exclusive strategic ...

Major deals, including Johnson & Johnson’s $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly ...

The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

One potentially serious complication of obstructive sleep apnea (OSA) is pulmonary hypertension (PH). Based on previous research that revealed involvement of perivascular immune and inflammatory ...

There are no systemic therapies with durable activity for malignant SFTs to date. The molecular hallmark of SFTs is a gene fusion between the NAB2 and STAT6 loci on chromosome 12, resulting in a ...

Solitary Fibrous Tumors (SFTs) are a rare malignancy defined by NAB2-STAT6 fusions. Because the molecular understanding of the disease is largely lacking, there are currently no targeted treatment ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cell signalling is the mechanism by which stimuli are transmitted via a signalling cascade to effector molecules that orchestrate the appropriate response. Types of cell signalling pathways ...